このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Oculis Holding マネジメント

マネジメント基準チェック /04

Oculis Holding'sの CEO はRiad Sherifで、 Dec2017年に任命され、の在任期間は 6.5年です。は、会社の株式の2.1%を直接所有しており、その価値は€ 9.61M 。経営陣と取締役会の平均在任期間はそれぞれ1.6年と1.6年です。

主要情報

Riad Sherif

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	6.5yrs
CEOの所有権	2.1%
経営陣の平均在職期間	1.6yrs
取締役会の平均在任期間	1.6yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Riad Sherif (56 yo)

6.5yrs

在職期間

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Riad Sherif	CEO & Director	6.5yrs	データなし	2.1% CHF 9.7m
Sylvia Cheung	Chief Financial Officer	3.8yrs	データなし	0.16% CHF 739.8k
Ramin Tadayoni	Chief Scientific Officer	less than a year	データなし	データなし
Virginia Dean	Chief Human Resources Officer	less than a year	データなし	データなし
Bastian Dehmel	Chief Development Officer	2.4yrs	データなし	データなし
Páll Jóhannesson	Chief Business Officer	3.8yrs	データなし	0.60% CHF 2.8m
Rebecca Weil	Chief Commercial Officer	less than a year	データなし	データなし
Snehal Shah	President of Research & Development	less than a year	データなし	データなし

1.6yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: CR5の経営陣は経験豊富とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Riad Sherif	CEO & Director	6.5yrs	データなし	2.1% CHF 9.7m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	データなし	データなし
Anthony Rosenberg	Independent Chairman	6.2yrs	データなし	0.23% CHF 1.1m
Christophe Baudouin	Member of Scientific Advisory Board	1.6yrs	データなし	データなし
Peter Kaiser	Member of Scientific Advisory Board	1.6yrs	データなし	データなし
Lionel Carnot	Independent Director	6.5yrs	データなし	データなし
Christina Ackermann	Independent Director	1.3yrs	データなし	0.028% CHF 129.7k
Quan Dong Nguyen	Member of Scientific Advisory Board	1.6yrs	データなし	データなし
Robert Warner	Director	less than a year	データなし	データなし
Arshad Khanani	Chair of Retina Scientific Advisory Board & Director	1.6yrs	データなし	データなし
Anat Loewenstein	Member of Scientific Advisory Board	1.6yrs	データなし	データなし
Pablo Villoslada	Member of Scientific Advisory Board	1.6yrs	データなし	データなし

1.6yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: CR5の取締役会は経験豊富ではない ( 1.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Oculis Holding マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Oculis Holding AG Announces Board and Committee Appointments

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

High number of new directors

High number of new directors

Recent updates

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings released: CHF2.97 loss per share (vs CHF12.95 loss in FY 2022)

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings released: CHF0.48 loss per share (vs CHF3.29 loss in 3Q 2022)

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

High number of new directors

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new directors

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04